Visceral adiposity, insulin resistance and cancer risk

Claire L Donohoe, Suzanne L Doyle, John V Reynolds, Claire L Donohoe, Suzanne L Doyle, John V Reynolds

Abstract

Background: There is a well established link between obesity and cancer. Emerging research is characterising this relationship further and delineating the specific role of excess visceral adiposity, as opposed to simple obesity, in promoting tumorigenesis. This review summarises the evidence from an epidemiological and pathophysiological perspective.

Methods: Relevant medical literature was identified from searches of PubMed and references cited in appropriate articles identified. Selection of articles was based on peer review, journal and relevance.

Results: Numerous epidemiological studies consistently identify increased risk of developing carcinoma in the obese. Adipose tissue, particularly viscerally located fat, is metabolically active and exerts systemic endocrine effects. Putative pathophysiological mechanisms linking obesity and carcinogenesis include the paracrine effects of adipose tissue and systemic alterations associated with obesity. Systemic changes in the obese state include chronic inflammation and alterations in adipokines and sex steroids. Insulin and the insulin-like growth factor axis influence tumorigenesis and also have a complex relationship with adiposity. There is evidence to suggest that insulin and the IGF axis play an important role in mediating obesity associated malignancy.

Conclusions: There is much evidence to support a role for obesity in cancer progression, however further research is warranted to determine the specific effect of excess visceral adipose tissue on tumorigenesis. Investigation of the potential mechanisms underpinning the association, including the role of insulin and the IGF axis, will improve understanding of the obesity and cancer link and may uncover targets for intervention.

Figures

Figure 1
Figure 1
Hallmarks of cancer and potential role of visceral obesity in tumorigenesis
Figure 2
Figure 2
Paracrine mechanisms linking adipose tissue and cancer development
Figure 3
Figure 3
Systemic alterations in visceral adiposity which may contribute to a pro-tumorigenic microenvironment.

References

    1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii. 1-253.
    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and Trends in Obesity Among US Adults, 1999-2008. JAMA: The Journal of the American Medical Association. 2010;303:235–241. doi: 10.1001/jama.2009.2014.
    1. Berghofer A, Pischon T, Reinhold T, Apovian C, Sharma A, Willich S. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008;8:200. doi: 10.1186/1471-2458-8-200.
    1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–2556. doi: 10.1210/jc.2004-0395.
    1. Vohl MC, Sladek R, Robitaille J, Gurd S, Marceau P, Richard D, Hudson TJ, Tchernof A. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res. 2004;12:1217–1222. doi: 10.1038/oby.2004.153.
    1. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316:129–139. doi: 10.1016/j.mce.2009.08.018.
    1. Despres J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–887. doi: 10.1038/nature05488.
    1. Nedungadi TP, Clegg DJ. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res. 2009;2:321–327. doi: 10.1007/s12265-009-9101-1.
    1. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Kalkhoff RK, Adams PW. Relation of Body Fat Distribution to Metabolic Complications of Obesity. J Clin Endocrinol Metab. 1982;54:254–260. doi: 10.1210/jcem-54-2-254.
    1. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis. 1990;10:497–511.
    1. Snijder MB, Dam RMV, Visser M, Seidell JC. What aspects of body fat are particularly hazardous and how do we measure them? International Journal of Epidemiology. 2006;35:83–92.
    1. van Kruijsdijk RCM, van der Wall E, Visseren FLJ. Obesity and Cancer: The Role of Dysfunctional Adipose Tissue. Cancer Epidemiology Biomarkers & Prevention. 2009;18:2569–2578. doi: 10.1158/1055-9965.EPI-09-0372.
    1. Okorodudu DO, Jumean MF, Montori VH, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systemic review and meta-analysis. Internation Journal of Obesity. 2010;34:791–799. doi: 10.1038/ijo.2010.5.
    1. Zhu S, Heshka S, Wang Z, Shen W, Allison DB, Ross R, Heymsfield S. Combination of BMI and waist circumference for identifying cardiovascular risk factors in whites. Obesity Research. 2004;12:633–645. doi: 10.1038/oby.2004.73.
    1. Kashihara H, Lee J, Kawakubo K, Tamura M, Akabayashi A. Criteria of Waist Circumference According to Computed Tomography-Measured Visceral Fat Area and the Clustering of Cardiovascular Risk Factors. Circ J. 2009;73:1881–1886. doi: 10.1253/circj.CJ-09-0183.
    1. Lemieux S, Prud'homme D, Bouchard C, Tremblav A, Després J-P. A single threshold value of waist girth identifies normal weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr. 1996;64:685–693.
    1. Balentine CJ, Marshall C, Robinson C, Wilks J, Anaya D, Albo D, Berger DH. Validating Quantitative Obesity Measurements in Colorectal Cancer Patients. Journal of Surgical Research. 2010;5:1–5.
    1. Björntorp P. Metabolic difference between visceral fat and subcutaneous abdominal fat. Diabetes Metab. 2000;26:13–12.
    1. Björntorp P. Abdominal obesity and the metabolic syndrome. Ann Med. 1992;24:465–468. doi: 10.3109/07853899209166997.
    1. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care. 2008;31:587–589.
    1. Oka R, Kobayashi J, Yagi K, Tanii H, Miyamoto S, Asano A, Hagishita T, Mori M, Moriuchi T, Kobayashi M. et al.Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. Diabetes Res Clin Pract. 2008;79:474–481.
    1. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Ramachandran S, Vasan S, Murabito JM, Meigs JB. et al.Abdominal Visceral and Subcutaneous Adipose Tissue Compartments:Association With Metabolic Risk Factors in the Framingham Heart Study. Circulation. 2007;116:39–48. doi: 10.1161/CIRCULATIONAHA.106.675355.
    1. Fund WCR. Book Food, nutrition, physical activity and the prevention of cancer: a global perspective. 2. City: American Institute for Cancer Research; 2007. Food, nutrition, physical activity and the prevention of cancer: a global perspective.
    1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578. doi: 10.1016/S0140-6736(08)60269-X.
    1. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S. et al.Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653–662. doi: 10.1016/S1470-2045(09)70159-7.
    1. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med. 1965;58:295–300.
    1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638. doi: 10.1056/NEJMoa021423.
    1. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301:2553–2562. doi: 10.1001/jama.2009.886.
    1. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB, Macdonald JS, Fuchs CS. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484–495. doi: 10.1002/cncr.11544.
    1. Haydon AM, Macinnis RJ, English DR, Giles GG. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 2006;55:62–67. doi: 10.1136/gut.2005.068189.
    1. Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell MJ, Wolmark N. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98:1647–1654. doi: 10.1093/jnci/djj442.
    1. Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC, Kreger BE. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord. 2004;28:559–567. doi: 10.1038/sj.ijo.0802606.
    1. Wang Y, Jacobs EJ, Patel AV, Rodriguez C, McCullough ML, Thun MJ, Calle EE. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. Cancer Causes Control. 2008;19:783–792. doi: 10.1007/s10552-008-9141-x.
    1. Steffen A, Schulze MB, Pischon T, Dietrich T, Molina E, Chirlaque MD, Barricarte A, Amiano P, Quiros JR, Tumino R. et al.Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2009;18:2079–2089. doi: 10.1158/1055-9965.EPI-09-0265.
    1. Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV. Obesity and gastrointestinal cancer. British Journal of Surgery. 2010;97:628–642. doi: 10.1002/bjs.7079.
    1. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol. 2006;169:1505–1522. doi: 10.2353/ajpath.2006.051090.
    1. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86:s836–842.
    1. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:385–391.
    1. Bowers K, Albanes D, Limburg P, Pietinen P, Taylor PR, Virtamo J, Stolzenberg-Solomon R. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol. 2006;164:652–664. doi: 10.1093/aje/kwj253.
    1. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001;10:937–941.
    1. Stocks T, Borena W, Strohmaier S, Bjørge T, Manjer J, Engeland A, Johansen D, Selmer R, Hallmans G, Rapp K. et al.Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can) International Journal of Epidemiology. 2010;39:660–667. doi: 10.1093/ije/dyp186.
    1. Stocks T, Lukanova A, Bjørge T, Ulmer H, Manjer J, Almquist M, Concin H, Engeland A, Hallmans G, Nagel G, Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can) Cancer. 2010.
    1. Bjørge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, Rapp K, Ulmer H, Almquist M, Concin H. et al.Metabolic Syndrome and Endometrial Carcinoma. American Journal of Epidemiology. 2010;171:892–902. doi: 10.1093/aje/kwq006.
    1. Häggström C, Stocks T, Rapp K, Bjørge T, Lindkvist B, Concin H, Engeland A, Manjer J, Ulmer H, Selmer R, Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can) International Journal of Cancer. 2010.
    1. Johansen D, Stocks T, Jonsson H, Lindkvist B, Björge T, Concin H, Almquist M, Häggström C, Engeland A, Ulmer H. et al.Metabolic Factors and the Risk of Pancreatic Cancer: A Prospective Analysis of almost 580,000 Men and Women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiology Biomarkers & Prevention. 2010;19:2307–2317. doi: 10.1158/1055-9965.EPI-10-0234.
    1. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738. doi: 10.1210/er.21.6.697.
    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. doi: 10.1016/S0092-8674(00)81683-9.
    1. Mantovani A. Cancer: Inflaming metastasis. Nature. 2009;457:36–37.
    1. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab. 2007;293:E1118–1128. doi: 10.1152/ajpendo.00435.2007.
    1. Vaupel P. The Role of Hypoxia-Induced Factors in Tumor Progression. Oncologist. 2004;9:10–17.
    1. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of Hypoxia-inducible Factor 1α in Common Human Cancers and Their Metastases. Cancer Research. 1999;59:5830–5835.
    1. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–355. doi: 10.1079/BJN20041213.
    1. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999;59:3915–3918.
    1. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277:38205–38211. doi: 10.1074/jbc.M203781200.
    1. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res. 2004;12:180–186. doi: 10.1038/oby.2004.24.
    1. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15:425–430. doi: 10.1158/1078-0432.CCR-08-0149.
    1. Elliott BE, Tam SP, Dexter D, Chen ZQ. Capacity of adipose tissue to promote growth and metastasis of a murine mammary carcinoma: effect of estrogen and progesterone. Int J Cancer. 1992;51:416–424. doi: 10.1002/ijc.2910510314.
    1. Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F, Gromova I. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics. 2005;4:492–522. doi: 10.1074/mcp.M500030-MCP200.
    1. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis. 2004;14:228–232. doi: 10.1016/S0939-4753(04)80048-6.
    1. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953–966. doi: 10.1016/S0899-9007(01)00672-4.
    1. Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev. 2006;27:449–467. doi: 10.1210/er.2005-0022.
    1. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830.
    1. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–1808.
    1. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest. 2006;116:33–35.
    1. Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R, Bouloumie A. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes. 2004;53:1285–1292. doi: 10.2337/diabetes.53.5.1285.
    1. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA. 2003;100:7265–7270. doi: 10.1073/pnas.1133870100.
    1. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785–1788.
    1. Bassols J, Ortega FJ, Moreno-Navarrete JM, Peral B, Ricart W, Fernandez-Real JM. Study of the proinflammatory role of human differentiated omental adipocytes. J Cell Biochem. 2009;107:1107–1117. doi: 10.1002/jcb.22208.
    1. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N. et al.The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–946. doi: 10.1038/90984.
    1. Schaffler A, Scholmerich J, Buchler C. Mechanisms of Disease: adipocytokines and visceral adipose tissue[mdash]emerging role in intestinal and mesenteric diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2:103–111. doi: 10.1038/ncpgasthep0090.
    1. Dieudonne M-N, Bussiere M, Dos Santos E, Leneveu M-C, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochemical and Biophysical Research Communications. 2006;345:271–279. doi: 10.1016/j.bbrc.2006.04.076.
    1. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101:2476–2481. doi: 10.1073/pnas.0308671100.
    1. Wang Y, Lam KSL, Xu A. Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res. 2007;17:280–282. doi: 10.1038/cr.2007.14.
    1. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301–316. doi: 10.1146/annurev.med.080708.082713.
    1. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114:71–83. doi: 10.1080/13813450801954303.
    1. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. doi: 10.1210/er.2005-0005.
    1. Cummings DE, Foster KE. Ghrelin-leptin tango in body-weight regulation. Gastroenterology. 2003;124:1532–1535. doi: 10.1016/S0016-5085(03)00350-0.
    1. Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. British Journal of Surgery. pp. 1020–1027.
    1. Jain SS, Bird RP. Elevated expression of tumor necrosis factor-alpha signaling molecules in colonic tumors of Zucker obese (fa/fa) rats. Int J Cancer. 2010;127:2042–2050. doi: 10.1002/ijc.25232.
    1. Rodeheffer MS, Birsoy K, Friedman JM. Identification of White Adipocyte Progenitor Cells In Vivo. Cell. 2008;135:240–249. doi: 10.1016/j.cell.2008.09.036.
    1. Zhang Y, Daquinag A, Traktuev DO, Amaya-Manzanares F, Simmons PJ, March KL, Pasqualini R, Arap W, Kolonin MG. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res. 2009;69:5259–5266. doi: 10.1158/0008-5472.CAN-08-3444.
    1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. doi: 10.1038/nature01322.
    1. Guiu B, Petit JM, Bonnetain F, Ladoire S, Guiu S, Cercueil J-P, Krausé D, Hillon P, Borg C, Chauffert B, Ghiringhelli F. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut. 2010;59:341–347. doi: 10.1136/gut.2009.188946.
    1. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134. doi: 10.1136/.
    1. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16:2533–2547. doi: 10.1158/1055-9965.EPI-07-0708.
    1. Calle EE. Obesity and cancer. BMJ. 2007;335:1107–1108. doi: 10.1136/bmj.39384.472072.80.
    1. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006;65:125–131. doi: 10.1111/j.1365-2265.2006.02560.x.
    1. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, Macdonald PC. Plasma Precursors of Estrogen. II. Correlation of the Extent of Conversion of Plasma Androstenedione to Estrone with Age. J Clin Endocrinol Metab. 1974;38:476–479. doi: 10.1210/jcem-38-3-476.
    1. Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, LeRoith D, Levy J, Sharoni Y. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology. 1996;137:1089–1095. doi: 10.1210/en.137.3.1089.
    1. Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD. Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States) Cancer Causes Control. 2003;14:75–84. doi: 10.1023/A:1022545017867.
    1. Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004;159:259–268. doi: 10.1093/aje/kwh041.
    1. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, Adam HO. A prospective study of obesity and cancer risk (Sweden) Cancer Causes Control. 2001;12:13–21. doi: 10.1023/A:1008995217664.
    1. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591. doi: 10.1038/nrc1408.
    1. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R. et al.Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95:1218–1226.
    1. Brochu M, Starling RD, Tchernof A, Matthews DE, Garcia-Rubi E, Poehlman ET. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J Clin Endocrinol Metab. 2000;85:2378–2384. doi: 10.1210/jc.85.7.2378.
    1. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–1603. doi: 10.1007/s00125-003-1228-z.
    1. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765–3773. doi: 10.1210/en.2003-0580.
    1. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002;32(Suppl 3):24–34.
    1. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med. 2002;113(Suppl 6A):3S–11S.
    1. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004. pp. 579–591.
    1. Moller DE, Flier JS. Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med. 1991;325:938–948. doi: 10.1056/NEJM199109263251307.
    1. Wajchenberg BL. Subcutaneous and Visceral Adipose Tissue: Their Relation to the MetabolicSyndrome. Endocr Rev. 2000;21:697–738. doi: 10.1210/er.21.6.697.
    1. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Johansen D, Concin H, Tretli S. et al.Blood Glucose and Risk of Incident and Fatal Cancer in the Metabolic Syndrome and Cancer Project (Me-Can): Analysis of Six Prospective Cohorts. PLoS Med. 2009;6:e1000201. doi: 10.1371/journal.pmed.1000201.
    1. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–165. doi: 10.1111/j.1467-789X.2004.00142.x.
    1. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. The American Journal of Clinical Nutrition. 2007;86:836S–842S.
    1. Hsing AW, Gao Y-T, Chua S, Deng J, Stanczyk FZ. Insulin Resistance and Prostate Cancer Risk. Journal of the National Cancer Institute. 2003;95:67–71. doi: 10.1093/jnci/95.1.67.
    1. Argiles JM, Lopez-Soriano FJ. Insulin and cancer (Review) Int J Oncol. 2001;18:683–687.
    1. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Archives Of Physiology And Biochemistry. 2008;114:63–70. doi: 10.1080/13813450801954451.
    1. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetologica. 2010;47:87–95. doi: 10.1007/s00592-010-0187-3.
    1. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A, Savage PJ. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;91:1147–1154. doi: 10.1093/jnci/91.13.1147.
    1. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28–36. doi: 10.1002/cncr.21950.
    1. Larsson SC, Giovannucci E, Wolk A. Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care. 2005;28:1805–1807. doi: 10.2337/diacare.28.7.1805.
    1. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, Hoffman B, Hood N. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Research and Treatment. 2002;74:65–76. doi: 10.1023/A:1016075709022.
    1. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP. et al.Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy. Journal of Clinical Oncology. 2004;22:439–445.
    1. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. Journal of Clinical Oncology. 2009;27:176–185. doi: 10.1200/JCO.2008.17.9945.
    1. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127:1044–1050. doi: 10.1053/j.gastro.2004.07.011.
    1. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA. 1976;73:4536–4540. doi: 10.1073/pnas.73.12.4536.
    1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928. doi: 10.1038/nrc2536.
    1. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47.
    1. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008;114:23–37. doi: 10.1080/13813450801969715.
    1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3–34.
    1. Schernhammer ES, Tworoger SS, Eliassen AH, Missmer SA, Holly JM, Pollak MN, Hankinson SE. Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer. 2007;14:721–732. doi: 10.1677/ERC-06-0080.
    1. Lukanova A, Soderberg S, Stattin P, Palmqvist R, Lundin E, Biessy C, Rinaldi S, Riboli E, Hallmans G, Kaaks R. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden) Cancer Causes Control. 2002;13:509–516. doi: 10.1023/A:1016392129279.
    1. Gram IT, Norat T, Rinaldi S, Dossus L, Lukanova A, Tehard B, Clavel-Chapelon F, van Gils CH, van Noord PAH, Peeters PHM. et al.Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes. 2006;30:1623–1631. doi: 10.1038/sj.ijo.0803324.
    1. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, Jansson J-O, Svensson J. The Role of Liver-Derived Insulin-Like Growth Factor-I. Endocr Rev. 2009;30:494–535. doi: 10.1210/er.2009-0010.
    1. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003;421:182–187. doi: 10.1038/nature01298.
    1. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M, Greenberg NM. Conditional Deletion of Insulin-like Growth Factor-I Receptor in Prostate Epithelium. Cancer Research. 2008;68:3495–3504. doi: 10.1158/0008-5472.CAN-07-6531.
    1. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease. Endocr Rev. 2009;30:586–623. doi: 10.1210/er.2008-0047.
    1. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–137. doi: 10.1016/S0304-3835(03)00159-9.
    1. Firth SM, Baxter RC. Cellular Actions of the Insulin-Like Growth Factor Binding Proteins. Endocr Rev. 2002;23:824–854. doi: 10.1210/er.2001-0033.
    1. Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H, Yoshida M, Naito AT, Nishi J, Ueno H, Umezawa A. et al.IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature. 2008;454:345–349. doi: 10.1038/nature07027.
    1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–518. doi: 10.1038/nrc1387.
    1. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006;66:10100–10111. doi: 10.1158/0008-5472.CAN-06-1684.
    1. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem. 2000;275:15099–15105. doi: 10.1074/jbc.M000089200.
    1. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 1993;90:11217–11221. doi: 10.1073/pnas.90.23.11217.
    1. Hellawell GO, Turner GDH, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the Type 1 Insulin-like Growth Factor Receptor Is Up-Regulated in Primary Prostate Cancer and Commonly Persists in Metastatic Disease. Cancer Research. 2002;62:2942–2950.
    1. Law JH, Habibi G, Hu K, Masoudi H, Wang MYC, Stratford AL, Park E, Gee JMW, Finlay P, Jones HE. et al.Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival. Cancer Research. 2008;68:10238–10246. doi: 10.1158/0008-5472.CAN-08-2755.
    1. Chan B, Lee A. Insulin Receptor Substrates (IRSs) and Breast Tumorigenesis. Journal of Mammary Gland Biology and Neoplasia. 2008;13:415–422. doi: 10.1007/s10911-008-9101-9.
    1. Guvakova MA. Insulin-like growth factors control cell migration in health and disease. The International Journal of Biochemistry & Cell Biology. 2007;39:890–909. doi: 10.1016/j.biocel.2006.10.013.
    1. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D. et al.Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. Clinical Cancer Research. 2007;13:3611–3616. doi: 10.1158/1078-0432.CCR-07-0268.
    1. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, Moorehead RA. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 2006;26:1636–1644.
    1. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study. Science. 1998;279:563–566. doi: 10.1126/science.279.5350.563.
    1. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer. Journal of the National Cancer Institute. 2002;94:1099–1106.
    1. Majeed N, Blouin M-J, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene. 2005;24:4736–4740. doi: 10.1038/sj.onc.1208572.
    1. Yang X-F, Beamer WG, Huynh H, Pollak M. Reduced Growth of Human Breast Cancer Xenografts in Hosts Homozygous for the lit Mutation. Cancer Research. 1996;56:1509–1511.
    1. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer. 2001;85:428–430. doi: 10.1054/bjoc.2001.1895.
    1. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D, Yakar S. Reduced Circulating Insulin-like Growth Factor I Levels Delay the Onset of Chemically and Genetically Induced Mammary Tumors. Cancer Research. 2003;63:4384–4388.
    1. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21:215–244. doi: 10.1210/er.21.3.215.
    1. Jenkins PJ. Cancers associated with acromegaly. Neuroendocrinology. 2006;83:218–223. doi: 10.1159/000095531.
    1. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: A preliminary report. Growth Hormone & IGF Research. 2007;17:54–57. doi: 10.1016/j.ghir.2006.10.007.
    1. Tibblin G, Eriksson M, Cnattingius S, Ekbom A. High Birthweight as a Predictor of Prostate Cancer Risk. Epidemiology. 1995;6:423–424. doi: 10.1097/00001648-199507000-00017.
    1. Sandhu MS, Luben R, Day NE, Khaw K-T. Self-Reported Birth Weight and Subsequent Risk of Colorectal Cancer. Cancer Epidemiology Biomarkers & Prevention. 2002;11:935–938.
    1. McCormack VA, Silva IdS, De Stavola BL, Mohsen R, Leon DA, Lithell HO. Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort. BMJ. 2003;326:248. doi: 10.1136/bmj.326.7383.248.
    1. Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev. 2008;17:880–888. doi: 10.1158/1055-9965.EPI-07-2500.
    1. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma Insulin-like Growth Factor (IGF) I, IGF-binding Protein 3, and Mammographic Density. Cancer Research. 2000;60:3744–3748.
    1. Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res. 2007;9:R18. doi: 10.1186/bcr1655.
    1. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. Journal of the National Cancer Institute. 1999;91:620–625. doi: 10.1093/jnci/91.7.620.
    1. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE. A Prospective Study of Plasma Insulin-like Growth Factor-1 and Binding Protein-3 and Risk of Colorectal Neoplasia in Women. Cancer Epidemiology Biomarkers & Prevention. 2000;9:345–349.
    1. Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E, Kaaks R. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 2002;50:642–646. doi: 10.1136/gut.50.5.642.
    1. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum Levels of Insulin-Like Growth Factor I (IGF-I), IGF-II, IGF-Binding Protein-3, and Prostate-Specific Antigen as Predictors of Clinical Prostate Cancer. J Clin Endocrinol Metab. 2000;85:4258–4265. doi: 10.1210/jc.85.11.4258.
    1. Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman U-H, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective Study. Journal of the National Cancer Institute. 2000;92:1910–1917. doi: 10.1093/jnci/92.23.1910.
    1. de Graaff LCG, Argente J, van Meurs JBJ, Uitterlinden AG, Hokken-Koelega ACS. Genetic Polymorphisms in the Locus Control Region and Promoter of GH1 Are Related to Serum IGF-I Levels and Height in Patients with Isolated Growth Hormone Deficiency and Healthy Controls. Hormone Research in Paediatrics. 2010;73:25–34. doi: 10.1159/000271913.
    1. Gu F, Schumacher FR, Canzian F, Allen NE, Albanes D, Berg CD, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Buring JE. et al.Eighteen Insulin-like Growth Factor Pathway Genes, Circulating Levels of IGF-I and Its Binding Protein, and Risk of Prostate and Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 2010;19:2877–2887. doi: 10.1158/1055-9965.EPI-10-0507.
    1. Wong H-L, DeLellis K, Probst-Hensch N, Koh W-P, Van Den Berg D, Lee H-P, Yu MC, Ingles SA. A New Single Nucleotide Polymorphism in the Insulin-Like Growth Factor I Regulatory Region Associates with Colorectal Cancer Risk in Singapore Chinese. Cancer Epidemiology Biomarkers & Prevention. 2005;14:144–151.
    1. McElholm AR, McKnight AJ, Patterson CC, Johnston BT, Hardie LJ, Murray LJ. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology. 2010;139:204–212 e203. doi: 10.1053/j.gastro.2010.04.014.
    1. Terry KL, Tworoger SS, Gates MA, Cramer DW, Hankinson SE. Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinogenesis. 2009;30:2042–2046. doi: 10.1093/carcin/bgp257.
    1. Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin G, Tang R, Dong J, Chen Y, Xu L. et al.A 3'-Untranslated Region Polymorphism in IGF1 Predicts Survival of Non-Small Cell Lung Cancer in a Chinese Population. Clinical Cancer Research. 2010;16:1236–1244. doi: 10.1158/1078-0432.CCR-09-2719.
    1. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE. et al.A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Molecular Genetics. 2010;19:3089–3101. doi: 10.1093/hmg/ddq210.
    1. Suga K, Imai K, Eguchi H, Hayashi S, Higashi Y, Nakachi K. Molecular significance of excess body weight in postmenopausal breast cancer patients, in relation to expression of insulin-like growth factor I receptor and insulin-like growth factor II genes. Cancer Science. 2001;92:127–134. doi: 10.1111/j.1349-7006.2001.tb01074.x.
    1. Papaxoinis K, Patsouris E, Kittas C, Nicolopoulou-Stamati P. Insulinlike growth factor I receptor and estrogen receptor [beta] expressions are inversely correlated in colorectal neoplasms and affected by the insulin resistance syndrome. Human Pathology. 2007;38:1037–1046. doi: 10.1016/j.humpath.2006.11.024.
    1. Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Hormone & IGF Research. 2004;14:337–375. doi: 10.1016/j.ghir.2004.06.001.
    1. Heemskerk VH, Daemen MARC, Buurman WA. Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine & Growth Factor Reviews. 1999;10:5–14. doi: 10.1016/S1359-6101(98)00022-7.
    1. Renier G, Clement I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology. 1996;137:4611–4618. doi: 10.1210/en.137.11.4611.
    1. Wu Y, Brodt P, Sun H, Mejia W, Novosyadlyy R, Nunez N, Chen X, Mendoza A, Hong S-H, Khanna C, Yakar S. Insulin-Like Growth Factor-I Regulates the Liver Microenvironment in Obese Mice and Promotes Liver Metastasis. Cancer Research. 2010;70:57–67. doi: 10.1158/0008-5472.CAN-09-2472.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa